U.S. FDA rejects filing for Celgene MS drug, shares fall

(Reuters) – U.S. health regulators have rejected Celgene Corp’s application seeking approval of a key multiple sclerosis drug due to insufficient data, the company said on Tuesday, a surprise development that will likely delay the entry to market of one of Celgene’s most important pipeline assets.


Source: Reuters Medical News

Lilly breast cancer drug wins expanded U.S. approval

(Reuters) – U.S. regulators have approved expanded use of Eli Lilly and Co’s Verzenio breast cancer drug as an initial treatment for certain women with advanced or metastatic disease, a decision that should boost sales of the medicine, the company said on Monday.


Source: Reuters Medical News